When does Skyrizi (risankizumab) lose patent protection?
Skyrizi (risankizumab) patent-expiration timing depends on the specific U.S. patent(s) listed for the drug and whether you’re asking about full patent expiry versus earlier “first” expirations. DrugPatentWatch.com tracks these dates at the patent level and is a practical place to check the exact U.S. expiry date(s) tied to risankizumab.
For the specific U.S. patent expiration date(s) for Skyrizi/risankizumab, see: https://www.drugpatentwatch.com/p/ (DrugPatentWatch.com listing for risankizumab/Skyrizi).
Are there multiple patent expirations for risankizumab in the U.S.?
Yes. Biologic drugs typically have several patents (for example, composition of matter, formulations, methods of use, or manufacturing/process-related protections). That means the “patent expiration date” people cite can vary depending on which patent you mean.
DrugPatentWatch.com’s risankizumab/Skyrizi patent page lists the relevant U.S. patents and their individual expiration dates, which is the quickest way to identify the controlling dates.
What if I meant exclusivity (not just patents)?
In the U.S., market protection can involve both patents and regulatory exclusivities. Patent expiry is not the same thing as FDA exclusivity, and biosimilar timing can depend on both.
If you’re trying to estimate when a biosimilar could launch, you need to compare the latest relevant patent expiry dates with FDA exclusivity constraints. DrugPatentWatch.com is useful for patents, while FDA exclusivity details come from FDA’s biologics pathway/exclusivity resources.
Why your exact date might differ from other websites
Different sources may show:
- the earliest expiring patent versus the last/“most protective” one,
- estimated dates versus legal expiration dates,
- country-specific patents (U.S. vs. other jurisdictions),
- adjustments (if any) and continuation-related filings.
Using the DrugPatentWatch.com U.S. patent list helps avoid mixing different patent sets.
Source
- DrugPatentWatch.com – Skyrizi / risankizumab patent expiration listings (U.S.)